Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
APS treatment suppressed abnormal glycolipid metabolism and insulin resistance following 8 weeks of catch‑up growth by improving hepatic SIRT1‑PPARα‑FGF21 intracellular signaling and reducing chronic inflammation, and by partially attenuating hepatic steatosis.
|
26323321 |
2015 |
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
We are the first to demonstrate that the SIRT1/HMGB1 pathway is a key therapeutic target for controlling NAFLD inflammation and that SalB confers protection against HFD- and PA-induced hepatic steatosis and inflammation through SIRT1-mediated HMGB1 deacetylation.
|
26525891 |
2015 |
Steatohepatitis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In mice, hepatic deletion of Sirt1 promotes steatosis, inflammation, and fibrosis in response to ethanol challenge.
|
24262277 |
2014 |
Steatohepatitis
|
0.400 |
Therapeutic
|
disease |
CTD_human |
CLOCK/BMAL1 regulates circadian change of mouse hepatic insulin sensitivity by SIRT1.
|
24442997 |
2014 |
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
CTD_human |
We investigated mechanisms by which SIRT1 controls hepatic steatosis in mice.
|
24184811 |
2014 |
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
SIRT1 activation by methylene blue, a repurposed drug, leads to AMPK-mediated inhibition of steatosis and steatohepatitis.
|
24486702 |
2014 |
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
CTD_human |
CLOCK/BMAL1 regulates circadian change of mouse hepatic insulin sensitivity by SIRT1.
|
24442997 |
2014 |
Steatohepatitis
|
0.400 |
Therapeutic
|
disease |
CTD_human |
We investigated mechanisms by which SIRT1 controls hepatic steatosis in mice.
|
24184811 |
2014 |
Steatohepatitis
|
0.400 |
Therapeutic
|
disease |
CTD_human |
The miR-34a/NAMPT axis presents a potential target for treating obesity- and aging-related diseases involving SIRT1 dysfunction like steatosis and type 2 diabetes.
|
23834033 |
2013 |
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
This review will discuss the latest advances in this field, focusing on beneficial roles of SIRT1 in hepatic lipid metabolism including its potential as a therapeutic target for treatment of steatosis and other obesity-related metabolic diseases.
|
23374725 |
2013 |
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Molecularly, prevention of steatosis in the absence of REGγ entails elevated SirT1, a deacetylase regulating autophagy and metabolism.
|
24011073 |
2013 |
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
CTD_human |
The miR-34a/NAMPT axis presents a potential target for treating obesity- and aging-related diseases involving SIRT1 dysfunction like steatosis and type 2 diabetes.
|
23834033 |
2013 |
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
CTD_human |
SIRT7 represses Myc activity to suppress ER stress and prevent fatty liver disease.
|
24210820 |
2013 |
Steatohepatitis
|
0.400 |
Therapeutic
|
disease |
CTD_human |
SIRT7 represses Myc activity to suppress ER stress and prevent fatty liver disease.
|
24210820 |
2013 |
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therefore, we investigated whether the beneficial effects of exendin-4 treatment on fatty liver are mediated via Sirt1 in high-fat (HF) diet-induced obese C57BL/6J mice and related cell culture models.
|
22363635 |
2012 |
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
CTD_human |
These studies indicate that SIRT1 serves as a negative regulator of UPR signaling in T2DM and that SIRT1 attenuates hepatic steatosis, ameliorates insulin resistance, and restores glucose homeostasis, largely through the inhibition of mTORC1 and ER stress.
|
21321189 |
2011 |
Steatohepatitis
|
0.400 |
Therapeutic
|
disease |
CTD_human |
These studies indicate that SIRT1 serves as a negative regulator of UPR signaling in T2DM and that SIRT1 attenuates hepatic steatosis, ameliorates insulin resistance, and restores glucose homeostasis, largely through the inhibition of mTORC1 and ER stress.
|
21321189 |
2011 |
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The degradation leads to inhibition of SIRT1 function, which contributes to development of hepatic steatosis.
|
21540183 |
2011 |
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
These studies indicate that SIRT1 serves as a negative regulator of UPR signaling in T2DM and that SIRT1 attenuates hepatic steatosis, ameliorates insulin resistance, and restores glucose homeostasis, largely through the inhibition of mTORC1 and ER stress.
|
21321189 |
2011 |
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
We therefore propose that the DBC1-SIRT1 interaction may serve as a new target for therapies aimed at nonalcoholic liver steatosis.
|
20071779 |
2010 |
Steatohepatitis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Downregulation of SIRT1 mRNA expression in VAT of SHS could be possible impairing mitochondria biogenesis and fatty acid oxidation, promoting severe steatosis in obese patients.
|
20033348 |
2010 |